Abstract:Primary Sjögren syndrome is an immune-mediated exocrinopathy characterized by lymphoplasmacytic infiltration of the salivary and lacrimal glands. Various systemic extraglandular disorders are associated with primary Sjögren syndrome, and the thorax is commonly affected. The pulmonary manifestations of primary Sjögren syndrome may be categorized as airway abnormalities, interstitial pneumonias, and lymphoproliferative disorders; in each category, bronchiectasis or centrilobular nodules, nonspecific interstitial… Show more
“…Respiratory manifestations in pSS are heterogeneous and may include: dry cough, diffuse panbronchiolitis (DPB), bronchiectasis, nonspecific interstitial pneumonia (NSIP), idiopathic pulmonary fibrosis (IPF), cryptogenic organizing pneumonia (COP), lung cysts, nodular opacities, follicular bronchiolitis, lymphoid interstitial pneumonia (LIP), pseudolymphoma, lymphomatoid granulomatosis, lymphoma (usually of mucosaassociated lymphoid tissue type-MALT), pulmonary amyloidosis, pulmonary hypertension and pleural involvement. 11,12 The mediastinal manifestations of pSS include lymphadenopathy, thymic lymphoid hyperplasia, multilocular thymic cysts and, rarely, MALT lymphoma. 11,12 Such a wide range of manifestations may lead to significant diagnostic and therapeutic difficulties.…”
Section: Discussionmentioning
confidence: 99%
“…11,12 The mediastinal manifestations of pSS include lymphadenopathy, thymic lymphoid hyperplasia, multilocular thymic cysts and, rarely, MALT lymphoma. 11,12 Such a wide range of manifestations may lead to significant diagnostic and therapeutic difficulties. Occasionally, a histopathological assessment of lung biopsy is needed.…”
Section: Discussionmentioning
confidence: 99%
“…In HRCT scans, bronchial wall thickening (8-68%), nodules (6-29%), bronchiectasis (5-46%), air trapping (32%) and ground-glass attenuation were most frequently observed. [11][12][13] According to available publications, the prevalence of respiratory manifestations in pSS is estimated to be about 9-12% and clinical features are present in about 43-75% of patients when radiology imaging such as chest X-ray, HRCT or MRI are performed.…”
Background. Pulmonary manifestations (PMs) in primary Sjögren's syndrome (pSS) are among the most frequent extraglandular complications, with reported prevalence varying widely (9-75%), depending on the methods of detection.
“…Respiratory manifestations in pSS are heterogeneous and may include: dry cough, diffuse panbronchiolitis (DPB), bronchiectasis, nonspecific interstitial pneumonia (NSIP), idiopathic pulmonary fibrosis (IPF), cryptogenic organizing pneumonia (COP), lung cysts, nodular opacities, follicular bronchiolitis, lymphoid interstitial pneumonia (LIP), pseudolymphoma, lymphomatoid granulomatosis, lymphoma (usually of mucosaassociated lymphoid tissue type-MALT), pulmonary amyloidosis, pulmonary hypertension and pleural involvement. 11,12 The mediastinal manifestations of pSS include lymphadenopathy, thymic lymphoid hyperplasia, multilocular thymic cysts and, rarely, MALT lymphoma. 11,12 Such a wide range of manifestations may lead to significant diagnostic and therapeutic difficulties.…”
Section: Discussionmentioning
confidence: 99%
“…11,12 The mediastinal manifestations of pSS include lymphadenopathy, thymic lymphoid hyperplasia, multilocular thymic cysts and, rarely, MALT lymphoma. 11,12 Such a wide range of manifestations may lead to significant diagnostic and therapeutic difficulties. Occasionally, a histopathological assessment of lung biopsy is needed.…”
Section: Discussionmentioning
confidence: 99%
“…In HRCT scans, bronchial wall thickening (8-68%), nodules (6-29%), bronchiectasis (5-46%), air trapping (32%) and ground-glass attenuation were most frequently observed. [11][12][13] According to available publications, the prevalence of respiratory manifestations in pSS is estimated to be about 9-12% and clinical features are present in about 43-75% of patients when radiology imaging such as chest X-ray, HRCT or MRI are performed.…”
Background. Pulmonary manifestations (PMs) in primary Sjögren's syndrome (pSS) are among the most frequent extraglandular complications, with reported prevalence varying widely (9-75%), depending on the methods of detection.
“…Beim primären Sjögren-Syndrom stehen drei meist koexistente pulmonale Manifestationsformen im Vordergrund [29], die im Folgenden dargestellt werden. …”
Section: Sjögren-syndromunclassified
“…Darüber hinaus können sich hyperplastische Veränderungen in den hilären und mediastinalen Lymphknotenstationen und im lymphoiden Gewebe des Mediastinums mit lymphoider Hyperplasie des Thymus und Thymuszysten manifestieren [29].…”
Systemic autoimmune diseases are responsible for about 25% of all deaths due to interstitial lung disease; therefore, an early identification of patients with pulmonary manifestation changes the management. Detection, differential diagnostic classification and staging of the pneumological pattern of findings are largely based on high-resolution computed tomography (HR-CT). The main differential diagnostic challenges are interstitial manifestations which present with radiological-histopathological phenotypes of interstitial pneumonia. The most common form of interstitial pulmonary reaction form of connective tissue diseases is the nonspecific interstitial pneumonia (NSIP) pattern. In rheumatoid arthritis, a usual interstitial pneumonia (UIP) pattern is dominant. Uncharacteristic reactions of airways and pleura can be the leading symptom or present as accompanying findings. A serious complication is pulmonary hypertension. Drug-induced lung lesions can present with similar HR-CT morphology as connective tissue diseases and can only be differentiated in the temporal and clinical context.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.